Russian Heart Failure Journal 2004year Current aspects of thrombosis prevention in patients with chronic heart failure and potentialities of enoxaparin
Current aspects of thrombosis prevention in patients with chronic heart failure and potentialities of enoxaparin
Olbinskaya L.I., Kochkareva Yu.B., Kolosova K.Yu.
Urgency. Venous thrombosis and thromboembolism are frequent in patients with chronic heart failure (CHF). Analysis of several clinical studies has shown that the low-molecular heparin enoxaparin is an efficient and safe means for prevention of venous thromboses in therapeutic patients. Aim: Evaluating the effect of enoxaparin on the hemostasis system in patients with severe CHF and optimizing the prevention of shin deep vein thromboses (DVT) and pulmonary thromboembolism (PTE) in these groups of patients. Material and methods. Eighteen patients with III–IV NYHA functional class CHF (mean left ventricular ejection fraction, 39%) were enrolled in the study. Enoxaparin 40 mg was injected subcutaneously once a day for 14 days. Dynamics of hemostasis system parameters was evaluated at baseline and at 2 weeks. Results. For 6 months of observation, in no case shin DVT or PTE was observed. The 2-week heparin treatment resulted in decreased levels of soluble fibrin-monomer complexes and fibrinogen and diminished thrombodynamic potential index. Conclusions: Enoxaparin decreased intravascular blood coagulation, which allowed efficient use of the drug for prevention of thromboses and thromboembolism in patients with CHF.